[go: up one dir, main page]

NO20051998L - Torke prosess - Google Patents

Torke prosess

Info

Publication number
NO20051998L
NO20051998L NO20051998A NO20051998A NO20051998L NO 20051998 L NO20051998 L NO 20051998L NO 20051998 A NO20051998 A NO 20051998A NO 20051998 A NO20051998 A NO 20051998A NO 20051998 L NO20051998 L NO 20051998L
Authority
NO
Norway
Prior art keywords
preservative sample
preservative
viscous liquid
sample
dry process
Prior art date
Application number
NO20051998A
Other languages
English (en)
Other versions
NO20051998D0 (no
NO342741B1 (no
Inventor
Yves Mayeresse
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32234471&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20051998(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0225543A external-priority patent/GB0225543D0/en
Priority claimed from GBGB0225520.6A external-priority patent/GB0225520D0/en
Priority claimed from GB0225532A external-priority patent/GB0225532D0/en
Priority claimed from GB0317371A external-priority patent/GB0317371D0/en
Priority claimed from GB0317381A external-priority patent/GB0317381D0/en
Priority claimed from GB0317380A external-priority patent/GB0317380D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of NO20051998D0 publication Critical patent/NO20051998D0/no
Publication of NO20051998L publication Critical patent/NO20051998L/no
Publication of NO342741B1 publication Critical patent/NO342741B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Sampling And Sample Adjustment (AREA)

Abstract

Foreliggende oppfinnelse angår en fremgangsmåte for å tørke biologiske og andre ustabile prøver slik at de kan konserveres som en svært viskøs væske. Fremgangsmåten omfatter trinnene med å fremstille en konserveringsprøve ved å oppløse/suspendere et aktivt agens i en løsning av et stabiliserende agens, utsette konserveringsprøven for slike temperatur og trykkbetingelser at konserveringsprøven taper løsningsmiddel ved evaporasjon uten frysing eller bobling for å danne et skum og fjerne løsningsmiddel til konserveringsprøven tørker og danner en svært viskøs væske.
NO20051998A 2002-11-01 2005-04-25 Fremgangsmåte for konservering av et aktivt agens, svært viskøs væske, immunogen sammensetning eller vaksine, fremgangsmåte for fremstilling av en vaksine samt kit. NO342741B1 (no)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0225543A GB0225543D0 (en) 2002-11-01 2002-11-01 Immunogenic composition
GBGB0225520.6A GB0225520D0 (en) 2002-11-01 2002-11-01 Drying process
GB0225532A GB0225532D0 (en) 2002-11-01 2002-11-01 Drying process
GB0317371A GB0317371D0 (en) 2003-07-24 2003-07-24 Immunogenic composition
GB0317381A GB0317381D0 (en) 2003-07-24 2003-07-24 Drying method
GB0317380A GB0317380D0 (en) 2003-07-24 2003-07-24 Drying method
PCT/EP2003/012191 WO2004039417A2 (en) 2002-11-01 2003-10-30 Drying process

Publications (3)

Publication Number Publication Date
NO20051998D0 NO20051998D0 (no) 2005-04-25
NO20051998L true NO20051998L (no) 2005-06-24
NO342741B1 NO342741B1 (no) 2018-08-06

Family

ID=32234471

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20052010A NO20052010L (no) 2002-11-01 2005-04-25 Immunogen sammensetning
NO20051998A NO342741B1 (no) 2002-11-01 2005-04-25 Fremgangsmåte for konservering av et aktivt agens, svært viskøs væske, immunogen sammensetning eller vaksine, fremgangsmåte for fremstilling av en vaksine samt kit.
NO20180874A NO344759B1 (no) 2002-11-01 2018-06-21 Fremgangsmåte for konservering av et aktivt agens.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20052010A NO20052010L (no) 2002-11-01 2005-04-25 Immunogen sammensetning

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20180874A NO344759B1 (no) 2002-11-01 2018-06-21 Fremgangsmåte for konservering av et aktivt agens.

Country Status (27)

Country Link
US (3) US8409587B2 (no)
EP (3) EP1575612B1 (no)
JP (2) JP4579156B2 (no)
KR (2) KR101058978B1 (no)
AR (2) AR041881A1 (no)
AT (1) ATE352316T1 (no)
AU (2) AU2003287980B2 (no)
BR (1) BR0315767A (no)
CA (2) CA2503871C (no)
CY (2) CY1119362T1 (no)
DE (1) DE60311526T2 (no)
DK (2) DK1556477T3 (no)
ES (3) ES2645924T3 (no)
HU (1) HUE034801T2 (no)
IL (2) IL168054A (no)
IS (2) IS7806A (no)
LT (2) LT2395073T (no)
MA (2) MA27551A1 (no)
MX (3) MXPA05004675A (no)
MY (2) MY145693A (no)
NO (3) NO20052010L (no)
NZ (2) NZ539613A (no)
PL (2) PL213647B1 (no)
PT (2) PT2395073T (no)
SI (2) SI2395073T1 (no)
TW (2) TWI332843B (no)
WO (2) WO2004039399A1 (no)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE352316T1 (de) 2002-11-01 2007-02-15 Glaxosmithkline Biolog Sa Immunogene zusammensetzung
US20080176209A1 (en) * 2004-04-08 2008-07-24 Biomatrica, Inc. Integration of sample storage and sample management for life science
JP4896006B2 (ja) * 2004-04-08 2012-03-14 バイオマトリカ， インコーポレイテッド ライフサイエンスのためのサンプル保存とサンプル管理との統合
US20060099567A1 (en) * 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
GB0409795D0 (en) * 2004-04-30 2004-06-09 Glaxosmithkline Biolog Sa Drying method
TWI398272B (zh) * 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
DK2283857T3 (da) * 2005-06-27 2019-10-28 Glaxosmithkline Biologicals Sa Vaccinesammensætning omfattende konjugerede native N. Meningitidis kapselpolysaccharider
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
EP1973406B1 (en) 2005-12-28 2014-03-12 Advanced Bionutrition Corporation A delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form
PT2097102E (pt) * 2006-09-07 2012-08-03 Glaxosmithkline Biolog Sa Vacina de combinação tendo quantidades reduzidas de antigénio de poliovírus
JP5285617B2 (ja) * 2006-12-18 2013-09-11 アドバンスド バイオニュートリション コーポレーション 生きたプロバイオティクスを含む乾燥食物製品
MX2009011837A (es) 2007-05-02 2010-04-22 Glaxosmithkline Biolog Sa Vacuna.
EP2148923B1 (en) * 2007-05-18 2012-08-22 MedImmune, LLC Preservation of bioactive materials by freeze dried foam
GB0711683D0 (en) * 2007-06-16 2007-07-25 Enigma Diagnostics Ltd Compositions
JP2010529850A (ja) * 2007-06-16 2010-09-02 エニグマ ディアグノスティックス リミテッド 組成物
CN101801343A (zh) * 2007-07-26 2010-08-11 圣诺菲·帕斯图尔有限公司 抗原佐剂组合物及其方法
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
US9623094B2 (en) 2009-03-27 2017-04-18 Advanced Bionutrition Corporation Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
CN106987525B (zh) 2009-05-26 2020-10-27 先进生物营养公司 包含生物活性微生物和/或生物活性材料的稳定干粉组合物及其制造方法
WO2011032108A2 (en) * 2009-09-13 2011-03-17 Vu Truong-Le Formulation for room temperature stabilization of a live attenuated bacterial vaccine
RU2535869C2 (ru) 2010-01-28 2014-12-20 Эдванст Бионутришн Корпорейшн Сухая стекловидная композиция для стабилизации и защиты биологически активного материала и способ ее получения
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
FR2960781B1 (fr) * 2010-06-07 2013-11-22 Sanofi Pasteur Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue
WO2012018639A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
US9376709B2 (en) 2010-07-26 2016-06-28 Biomatrica, Inc. Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures
PL2603100T3 (pl) 2010-08-13 2019-06-28 Advanced Bionutrition Corp. Kompozycja stabilizująca przechowywanie na sucho materiałów biologicznych
WO2012028315A1 (en) 2010-09-02 2012-03-08 Sanofi Pasteur Sa A stabilizer for the preparation of a dry polio injectable vaccine composition
EP2646052B1 (en) 2010-12-02 2017-03-29 Oncolytics Biotech Inc. Lyophilized viral formulations
CN103347535B (zh) 2010-12-02 2015-11-25 昂科利蒂克斯生物科技公司 液体病毒制剂
US8512679B2 (en) 2011-03-04 2013-08-20 Elwha Llc Glassy compositions
KR20140066124A (ko) * 2011-04-07 2014-05-30 글락소스미스클라인 엘엘씨 점도가 감소된 제제
CA2832556A1 (en) * 2011-04-07 2012-10-11 Glaxosmithkline Llc Formulations with reduced viscosity
EP2524701A3 (en) 2011-05-20 2012-12-19 Nitto Denko Corporation Pharmaceutical composition and method for producing the same
US20140302021A1 (en) 2011-10-25 2014-10-09 Onclave Therapeutics Limited Antibody formulations and methods
WO2014100755A2 (en) 2012-12-20 2014-06-26 Biomatrica, Inc. Formulations and methods for stabilizing pcr reagents
WO2015050177A1 (ja) * 2013-10-03 2015-04-09 日東電工株式会社 インフルエンザワクチン乾燥製剤、及び、インフルエンザワクチン乾燥製剤の製造方法
AU2014368594B2 (en) * 2013-12-19 2020-03-05 Janssen Vaccines & Prevention B.V. Improved formulations for virosomes
US9902764B2 (en) 2014-02-11 2018-02-27 Massachusetts Institute Of Technology Full spectrum anti-dengue antibody
EP3154338B1 (en) 2014-06-10 2020-01-29 Biomatrica, INC. Stabilization of thrombocytes at ambient temperatures
AR101256A1 (es) * 2014-07-21 2016-12-07 Sanofi Pasteur Composición vacunal que comprende ipv y ciclodextrinas
EP3317395B1 (en) 2015-06-30 2020-07-15 Société des Produits Nestlé S.A. Composition suitable for protecting microorganisms
MY194231A (en) 2015-07-29 2022-11-23 Advanced Bionutrition Corp Stable dry probiotic compositions for special dietary uses
BR112018004400A2 (pt) * 2015-09-04 2018-12-04 Inventprise Llc composições de vacina vlp estabilizadas
KR102787387B1 (ko) 2015-12-08 2025-03-26 바이오매트리카 인코포레이티드 적혈구 침강 속도의 감소
WO2018045286A1 (en) 2016-09-02 2018-03-08 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
CA3097058A1 (en) * 2018-04-16 2019-10-24 Merck Patent Gmbh Additives for protein formulations to improve thermal stability
SG11202102876XA (en) * 2018-09-28 2021-04-29 Otsuka Pharma Factory Inc Mammal cell preserving solution containing acarbose or stachyose
WO2020127730A1 (en) 2018-12-20 2020-06-25 Intervet International B.V. Prime-boost vaccination regimen

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US509893A (en) * 1893-12-05 William griesser
DE1157734B (de) 1961-08-16 1963-11-21 Behringwerke Ag Verfahren zur Herstellung von haltbaren, oral zu verabreichenden Poliomyelitisvirus-Praeparaten
US3767790A (en) * 1972-02-11 1973-10-23 Nat Patent Dev Corp Microorganisms
US3929132A (en) * 1973-04-10 1975-12-30 Alza Corp Osmotic dispenser
DE3071552D1 (en) 1979-09-21 1986-05-22 Hitachi Ltd Semiconductor switch
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
GB8323094D0 (en) 1983-08-26 1983-09-28 Franks F Preservation of cells
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
EP0229810B1 (en) 1985-07-09 1991-10-16 Quadrant Bioresources Limited Protection of proteins and the like
GB8604983D0 (en) * 1986-02-28 1986-04-09 Biocompatibles Ltd Protein preservation
GB8715238D0 (en) 1987-06-29 1987-08-05 Quadrant Bioresources Ltd Food process
GB8801338D0 (en) 1988-01-21 1988-02-17 Quadrant Bioresources Ltd Preservation of viruses
DE3819530A1 (de) * 1988-06-08 1989-12-21 Westphal Geb Jauch Christel Dr Verfahren, traeger und testsatz fuer die kultivierung und mikroskopische untersuchung von zellen
DE68929323T2 (de) 1988-12-16 2002-04-18 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Pneumolysin-mutanten und pneumokokken-impfstoffe daraus
ZA907737B (en) 1989-09-29 1991-07-31 Nisshin Oil Mills Ltd Stable immunogen composition for oral administration
JPH03161441A (ja) 1989-11-20 1991-07-11 Senjiyu Seiyaku Kk メイラード反応阻害剤
CA2087160A1 (en) 1990-07-16 1992-01-17 P. Frederick Sparling Antigenic iron repressible proteins from n. meningitidis related to the hemolysin family of toxins
DE69133334T2 (de) 1990-08-23 2004-05-13 University Of North Carolina At Chapel Hill Transferrin bindende proteine aus neisseria-gonorrhoeae und neisseria-meningitidis
US5912336A (en) 1990-08-23 1999-06-15 University Of North Carolina At Chapel Hill Isolated nucleic acid molecules encoding transferrin binding proteins from Neisseria gonorrhoeae and Neisseria meningitidis
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
FR2682041B1 (fr) 1991-10-03 1994-01-14 Pasteur Merieux Serums Vaccins Vaccin contre les infections a neisseria meningitidis.
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
ATE245446T1 (de) 1992-02-11 2003-08-15 Jackson H M Found Military Med Dualer träger für immunogene konstrukte
JP3368902B2 (ja) 1992-03-02 2003-01-20 カイロン エセ．ピー．アー． ワクチンおよび診断に有用なＨｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉタンパク質
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
RU2160120C2 (ru) 1992-05-23 2000-12-10 Смитклайн Бичам Байолоджикалс С.А. Комбинированная вакцина на основе поверхностного антигена вируса гепатита в, способ ее получения и способ предупреждения инфекции гепатита в у человека
FR2692592B1 (fr) 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
ATE176157T1 (de) 1992-10-27 1999-02-15 American Cyanamid Co Pädiatrische kombinationsvakzine mit verbesserter immunogenizität jeder vakzine komponente
PT699076E (pt) 1993-05-18 2003-03-31 Univ Ohio State Res Found Vacina contra a otite media
CA2196415A1 (en) 1994-08-09 1996-02-22 Katsuhiko Ooyama Peroral immunogen composition and process for producing the same
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6265567B1 (en) 1995-04-07 2001-07-24 University Of North Carolina At Chapel Hill Isolated FrpB nucleic acid molecule
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
CN1245957C (zh) * 1995-06-07 2006-03-22 廓德伦特控股剑桥有限公司 将物质稳定掺入干燥泡沫玻璃基质中的方法以及由此制得的组合物
JP4233113B2 (ja) 1995-06-07 2009-03-04 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム 多糖類抗原−キャリア蛋白接合体および遊離キャリア蛋白を有してなるワクチン
JPH11507214A (ja) 1995-06-07 1999-06-29 バイオケム ヴァシーンズ インク． Ｈｓｐ７０ファミリーに属する連鎖球菌の熱ショック蛋白質メンバー
EA199700413A1 (ru) 1995-06-23 1998-08-27 Смитклайн Бичам Байолоджикалз, С.А. Композиция, содержащая вакцину и конъюгат антигена и полисахарида, адсорбированные на фосфате алюминия
DE19543770C2 (de) 1995-11-24 1998-11-05 Metallgesellschaft Ag Vorrichtung zur Messung von kondensierter Feuchtigkeit in Vorrichtungen und/oder Rohrleitungen der chemischen Technik und deren Verwendung
AU1671197A (en) 1996-02-13 1997-09-02 Nisshin Oil Mills, Ltd., The Vaccine-containing emulsion and vaccine-containing powder for oral administration and process for producing the same
ATE323721T1 (de) 1996-05-01 2006-05-15 Univ Rockefeller Cholin-bindendes protein, welches als gegen pneumokokken gerichtetes vakzin verwendet wird
US5766520A (en) 1996-07-15 1998-06-16 Universal Preservation Technologies, Inc. Preservation by foam formation
CA2256333A1 (en) * 1996-05-29 1997-12-04 Victor Bronshtein Long-term shelf preservation by vitrification
JP3280675B2 (ja) 1996-07-02 2002-05-13 コノート ラボラトリーズ リミテッド 多価ｄｔｐポリオワクチン
FR2751000B1 (fr) 1996-07-12 1998-10-30 Inst Nat Sante Rech Med Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques
DE19630390A1 (de) 1996-07-26 1998-01-29 Chiron Behring Gmbh & Co Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
DE69739981D1 (de) 1996-10-31 2010-10-14 Human Genome Sciences Inc Streptococcus pneumoniae-Antigene und Impfstoffe
US6051238A (en) * 1996-12-20 2000-04-18 Merck & Co., Inc. Stabilizers for lyophilized mumps vaccines
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
SE511963C2 (sv) 1997-04-23 1999-12-20 Ericsson Telefon Ab L M Anordning och förfarande för bestämning av linjespänning i en abonnentlinjekrets
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
WO1999003884A2 (en) 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
WO1999013906A1 (en) * 1997-09-15 1999-03-25 Pasteur Merieux Msd Multivalent vaccines
CA2307846A1 (en) 1997-11-21 1999-06-03 Genset S.A. Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
EP1032647B1 (en) * 1997-11-26 2006-03-29 Universal Preservation Technologies, Inc. Preservation of sensitive biological samples by vitrification
EP2228384A1 (en) 1997-11-28 2010-09-15 Merck Serono Biodevelopment Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
DK1047784T4 (en) 1998-01-14 2015-06-15 Novartis Vaccines & Diagnostic NEISSERA meningitidis ANTIGENS
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
ES2343492T3 (es) 1998-04-07 2010-08-02 Medimmune, Llc Derivados de proteinas neumococicas de union a colina para vacunas.
GB9807721D0 (en) 1998-04-08 1998-06-10 Chiron Spa Antigen
MX343752B (es) 1998-05-01 2016-11-22 Novartis Vaccines & Diagnostics Inc Antigenos de neisseria meningitidis y composiciones que los contienen.
US6306345B1 (en) * 1998-05-06 2001-10-23 Universal Preservation Technologies, Inc. Industrial scale barrier technology for preservation of sensitive biological materials at ambient temperatures
AU1202200A (en) 1998-10-09 2000-05-01 Chiron Corporation Neisseria genomic sequences and methods of their use
EP1123403A1 (en) 1998-10-22 2001-08-16 The University Of Montana OMP85 PROTEINS OF $i(NEISSERIA GONORRHOEAE) AND $i(NEISSERIA MENINGITIDIS), COMPOSITIONS CONTAINING SAME AND METHODS OF USE THEREOF
JP2002529069A (ja) 1998-11-12 2002-09-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア クラミジア・ニューモニエのゲノム配列
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
EP1162999B1 (en) 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
EP1233784B1 (en) 1999-12-02 2008-07-09 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for stabilizing biological molecules upon lyophilization
NZ520466A (en) 2000-01-17 2003-09-26 Chiron S Outer membrane vesicle (OMV) vaccine comprising n. meningitidis serogroup B outer membrane proteins
ATE503837T1 (de) 2000-02-28 2011-04-15 Novartis Vaccines & Diagnostic Hybride expression neisserscher proteine
WO2002000249A2 (en) 2000-06-29 2002-01-03 Glaxosmithkline Biologicals S.A. Multivalent vaccine composition
AU2001276619A1 (en) 2000-07-03 2002-01-14 Chiron S.P.A. Immunisation against chlamydia pneumoniae
KR100385711B1 (ko) * 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
EP1328543B1 (en) 2000-10-27 2009-08-12 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups a & b
CN100350972C (zh) 2001-07-26 2007-11-28 启龙股份公司 含有铝佐剂和组氨酸的疫苗
AU2003247337B2 (en) * 2002-04-11 2007-09-06 Medimmune, Llc Preservation of bioactive materials by freeze dried foam
ATE352316T1 (de) * 2002-11-01 2007-02-15 Glaxosmithkline Biolog Sa Immunogene zusammensetzung
GB0409795D0 (en) 2004-04-30 2004-06-09 Glaxosmithkline Biolog Sa Drying method
US9473463B2 (en) 2014-07-29 2016-10-18 Combined Conditional Access Development & Support, LLC Control word and associated entitlement control message caching and reuse

Also Published As

Publication number Publication date
PL377170A1 (pl) 2006-01-23
MY145693A (en) 2012-03-30
EP2395073A2 (en) 2011-12-14
CY1119504T1 (el) 2018-03-07
PL376950A1 (pl) 2006-01-09
MXPA05004528A (es) 2005-07-26
PL213647B1 (pl) 2013-04-30
MXPA05004675A (es) 2005-06-08
US7927858B2 (en) 2011-04-19
KR20050084626A (ko) 2005-08-26
EP1575612B1 (en) 2007-01-24
WO2004039417A2 (en) 2004-05-13
US8409587B2 (en) 2013-04-02
BR0315767A (pt) 2005-09-06
CA2503946C (en) 2016-08-16
NO20052010L (no) 2005-06-24
AU2003287980B2 (en) 2009-06-25
EP1575612A1 (en) 2005-09-21
NO20180874A1 (no) 2005-06-24
NZ539613A (en) 2008-09-26
EP2395073B1 (en) 2017-09-06
JP2006504801A (ja) 2006-02-09
LT1556477T (lt) 2017-10-25
LT2395073T (lt) 2017-11-10
PT1556477T (pt) 2017-11-14
US20060127415A1 (en) 2006-06-15
AU2003287980A1 (en) 2004-05-25
NO20051998D0 (no) 2005-04-25
HUE034801T2 (en) 2018-02-28
IL168052A (en) 2015-03-31
JP2006512406A (ja) 2006-04-13
WO2004039417A3 (en) 2004-12-16
NO342741B1 (no) 2018-08-06
SI1556477T1 (sl) 2017-12-29
KR101130948B1 (ko) 2012-03-30
WO2004039399A1 (en) 2004-05-13
AU2003278166B2 (en) 2009-01-29
DE60311526T2 (de) 2007-10-31
NO344759B1 (no) 2020-04-14
DK1556477T3 (en) 2017-10-23
MA27551A1 (fr) 2005-10-03
CA2503871C (en) 2012-12-11
US20060127414A1 (en) 2006-06-15
NO20052010D0 (no) 2005-04-25
JP4579156B2 (ja) 2010-11-10
AR041880A1 (es) 2005-06-01
PT2395073T (pt) 2017-11-24
TW200501981A (en) 2005-01-16
ES2645924T3 (es) 2017-12-11
IL168052A0 (en) 2011-08-01
US8449865B2 (en) 2013-05-28
EP1556477B1 (en) 2017-08-09
US20110159038A1 (en) 2011-06-30
MA27644A1 (fr) 2005-12-01
SI2395073T1 (sl) 2017-12-29
IS7806A (is) 2005-04-18
KR20050075766A (ko) 2005-07-21
ES2649048T3 (es) 2018-01-09
EP2395073A3 (en) 2012-01-25
PL215237B1 (pl) 2013-11-29
MY132859A (en) 2007-10-31
CY1119362T1 (el) 2018-03-07
TW200501980A (en) 2005-01-16
NZ539706A (en) 2008-03-28
DE60311526D1 (de) 2007-03-15
AR041881A1 (es) 2005-06-01
HK1085380A1 (en) 2006-08-25
CA2503871A1 (en) 2004-05-13
ES2280809T3 (es) 2007-09-16
KR101058978B1 (ko) 2011-08-23
TWI332843B (en) 2010-11-11
MX343419B (es) 2016-11-04
IS3028B (is) 2021-05-15
IL168054A (en) 2011-06-30
CA2503946A1 (en) 2004-05-13
IS7805A (is) 2005-04-18
DK2395073T3 (en) 2017-10-23
AU2003278166A1 (en) 2004-05-25
ATE352316T1 (de) 2007-02-15
EP1556477A2 (en) 2005-07-27

Similar Documents

Publication Publication Date Title
NO20051998L (no) Torke prosess
AR125151A2 (es) Composición estabilizadora de almacenamiento en seco para materiales biológicos
Ward et al. The principles of freeze-drying and application of analytical technologies
NO990158D0 (no) Konservering ved skumdannelse
Adams et al. The principles of freeze-drying
WO2005105978A3 (en) Drying process for preserving an active agent as a highly viscous liquid
WO1998002240B1 (en) Preservation by foam formation
CA1037858A (en) Freeze-drying process
Kumar Lyophilization: An important formulation technique
NO20044749L (no) Stabilisert naturlig cannabinoidformulering
CN105586336A (zh) 一种生物dna和rna室温保存卡及其制作方法
CN113074519B (zh) 一种高效去除门冬胰岛素中残留有机溶剂的方法
BR102014025999B1 (pt) método para a preparação de um extrato seco
CN107469379A (zh) 一种样品中残留水溶性有机溶剂的去除方法
CN206507214U (zh) 真空干燥萃取系统
RU2017136453A (ru) Способ ацетилирования древесины
Dhangar et al. Evaporation A unit operation in pharmaceutical industry
TWI623270B (zh) 真空乾燥萃取系統及其操作方法
BR0315733A (pt) Método para conservar um agente ativo, liquido altamente viscoso, composição imunogênica ou vacina, método para fabricar uma vacina, e, kit
Moonchai et al. Effect of Variables on Honey Dehydration
Bianco Influence of Freezing Protocols and the Role of Excipients on Stability and Enzymatic Activity
RU2277542C1 (ru) Способ очистки сухого пектинового экстракта
Pandhare et al. REVIEW ON: LYOPHILIZATION PROCESS OF PHARMACEUTICALS.
Sun 86. The cavitation–implosion hypothesis of freeze drying damage to biological materials
Adiya et al. Vacuum Contact Drying of Pharmaceutical Powders with and without agitation: A Comparison

Legal Events

Date Code Title Description
MK1K Patent expired